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ABSTRACT 
 
Context: Non Syndromic Cleft lip/Palate is a congenital anomaly with significant medical, psychological and social 
ramifications.  There is sufficient evidence to hypothesize that locus for this condition can be identified by candidate 
genes. Aims: To amplify the chosen region TGF-β3 gene, investigate the degree of association and perform a 
mutation research from raichur cleft lip and palate patient sample. Settings and Design: Case history and clinical 
examination of the patient were recorded to rule. Written consent was obtained from patients and controls for in vivo 
study. Study was designed in 4 steps.Methods and Material: Blood samples were collected from 40 subjects 
having Non Syndromic Cleft lip/Palate and 40 controls. Genomic DNA was extracted, Polymerase Chain Reaction 
(PCR) and The obtained fragments were sequenced and TGF-β3 gene polymorphisms were assessed based on the 
number of CA repeats. Statistical analysis: Chi- square test with P value at 95 % confidence intervals. Results: 
Results showed a significant difference in the number of CA repeats between the case and the control groups 
(p=0.01). Conclusions: From a genetically diverse etiology TGF-β3 gene variant may be a good screening marker 
for Non Syndromic Cleft lip /Palate in Raichur Patients. 
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Introduction 
 
 
The development of the head and face is one of the 
most complex and tightly controlled events during 
embryonic development. Disturbances during the 
period critical for the formation of face (7-10 weeks for 
humans) may lead to orofacial clefts[1].  
 
Non-syndromic cleft lip with or without cleft palate 
(NSCL/CLP) is the most common craniofacial 
anomaly. Its birth prevalence ranges from 1/500 to 
1/2000, depending on geographical origin. 
Approximately two thirds of the cases are not 
accompanied by other anomalies and are called non 
syndromic (NS) [2]. 
 
_______________________________ 
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It is very likely that both genetic and environmental 
factors contribute to this malformation. Genetic factors 
contribute approximately 30% towards cleft lip and 
palate whereas environmental factors are the major 
contributors approximately 70% of cleft lip and palate. 
It has been reported that Cleft lip and palate occurs 
more frequently in males, while the sex bias is reversed 
for Cleft palate, which is more common in females[3]. 
The etiology seems complex, but genetics plays a 
major role. 
Over the past decade, genetic linkage and association 
analyses have provided evidence to support the 
involvement of several genes and chromosomal 
regions, among them loci at 1q32 (IRF6), 2p13 
(TGFA), 4p16 (MSX1), 6p23-25, 14q24 (TGFB3), 
17q21 (RARA), and 19q13 (BCL3, TGFB1) have the 
most supporting data[4]. 
Transforming Growth Factor-Beta 3 (TGF-β3) is one 
of the strongest candidate gene for cleft lip and palate 
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in humans [4,5]. TGF-β3 (located on 14q24) has a 
broad spectrum of biological activities and is known to 
induce palatal fusion 6 and in recent years a large 
number of studies have been conducted to elucidate the 
relationship of TGF-β3 and cleft lip and palate [7-9]. 
As none of the studies included patients of the Indian 
subcontinent who are genetically distinct from the 
other study populations, this study was done to detect 
the presence of TGF-β3 gene polymorphisms in non 
syndromic cleft lip and palate in Indian patients. 
The advents of molecular biology and advanced 
genetic techniques have allowed uncovering, 
characterizing and ultimately manipulating the genes 
that make up the genome. It is becoming clear that the 
molecular centre of embryogenic morphology resides 
at the level of gene.  
Material and methods  
 
Patient samples  
 
The study was approved by the Ethics Committee of 
Medical College Hospital. Forty patients with non-
syndromic cleft lip with cleft palate were selected and 
informed consent was obtained. Subjects with known 
teratogenic exposure and other recognized syndromes 
as well as children with other major or multiple minor 
defects and/or developmental delay as determined from 
the demographic details, perinatal history, teratogenic 
exposure and family history were excluded. Forty 
unaffected individuals from the same geographic area 
who had no craniofacial anomaly or other congenital 
disease and no family history of craniofacial 
malformation were included in the study as controls. 
Peripheral blood sample (10 ml) was collected by 
venipuncture from all cases.  
 
DNA extraction and amplification 
 
 A modified protocol for standard organic extraction 
method was used for DNA extraction from 
lymphocytes. Polymerase chain reactions were 
performed to amplify the extracted DNA samples and 
assessed for the allelic variants using specific primers 
for TGF-β3 gene.  
 
TGF-β3 primers 
 
Sense (Forward) primer: 
 AGATTCTGGCTTCCACGAAA  
 
Antisense (reverse) primer:  
GCAAGCAGGGATAATAACAGCA. 
 
After completion of the PCR reaction, an agarose gel 
was run to identify amplified PCR products. These 
fragments were then cut out and subjected to to sequen-
cing PCR using the ABI prism Big. Dye Terminator 
Cycle sequencing ready reaction kit version 3.1. The 
product obtained from sequencing PCR was subjected 
to isopropanol precipitation to remove protein and 
other contaminants and then sent for sequencing. 
Analysis of sequencing results 
 
The TGF-β3 gene has a CA repeat sequence, and the 
polymorphism is dependent on the frequency of CA 
repeats. The sequences of the amplified DNA 
fragments of TGF-β3 gene were analyzed using Bioedit 
sequence analyzer software.  
 
Statistical procedure used 
Chi –square test was used to compare the case and 
control groups. 
Results 
 
The number of CA repeats in the DNA sequence of the 
cases was compared with the number of CA repeats in 
controls; 23 out of a total of 40 samples from the case 
group showed 10 CA repeats, whereas 14 of them had 
9 CA repeats and 3 samples had 6 CA repeats. In the 
control group 29 out of 40 samples had 9 CA repeats 
and only 11 had 10 CA repeats (Table 1). The 
significance of the results obtained was statistically 
analyzed using chi-square test. A chi-square value of > 
5.99 and a ‘p’ value of <0.05 is considered statistically 
significant. The chi-square calculated with our data 
was 12.446 with a corresponding p value of 0.01. Thus, 
we observed that the difference between the Non-
syndromic CLCP cases and the control group in terms 
of number of CA repeats representing the TGF-β3 
polymorphisms is highly significant. 
 
Table 1: Results of TGF-β3 Polymorphisms as determined by CA repeats in samples 
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TGF beta 3 Polymorphisms 
 
Controls 
 
Subjects (Non-syndromic 
CLCP) 
9 CA repeats 29 14 
9 CA repeats 11 23 
Others 0 3 
Total Cases 40 40 
 
Discussion  
 
The development of orofacial region relies on the in-
terplay of a vast range of genetic and epigenetic factors 
[10]. When these factors are disrupted either at the 
gene level, due to mutations or by disruption of epi-
genetic regulation by environmental teratogens could 
lead to orofacial clefting. Patients with orofacial clefts 
require surgical, nutritional, dental, speech, medical 
and behavioral interventions and impose a substantial 
emotional and economic burden on the society. These 
issues, along with the relatively high prevalence of 
orofacial clefts, emphasize the importance of unders-
tanding the underlying causes of these defects. Most 
orofacial clefts are caused by the interaction between 
genetic and environmental factors [11]. Genetic factors 
create susceptibility for clefts, and when environmental 
factors (ie, triggers) interact with a genetically 
susceptible genotype, a cleft develops during an early 
stage of development [12]. The organisation of the fa-
cial structures requires tissues to proliferate, fuse and 
differentiate. Palatogenesis involves fusion of the me-
dial edge epithelium (MEE) of the approximating pa-
latal shelves with each other via numerous desmosome 
contacts to form a midline palatal seam [13,14]. This 
seam rapidly degenerates allowing mesenchymal cells 
to flow across the now intact horizontal palate. TGF-β3 
is found in the epithelial component of the shelves and 
in the medial edge epithelium (MEE). TGF-β3 plays a 
crucial role in these initial adhesive interactions [15]. 
TGF-β3 knock out mouse exhibits cleft palate through 
failure of palatal shelf fusion [16]. Although the palatal 
shelves otherwise develop normally, they show a 
marked reduction in the filopodia and show down-
regulation of condroitin sulphate proteoglycan on the 
apical surface of the MEE [17,18], both of which are 
required for efficient MEE adhesion [19,20].  
A large number of studies [21-24] have been carried 
out to elucidate the role of TGF-β3 gene polymor-
phisms in the etiopathogenesis of cleft lip and palate of 
which some studies, such as that of Vieira AR et al [5] 
on south American population and Lidral AC et al [22] 
on Philippine population, have yielded positive 
associations, while a few studies did not show any 
significant association, such as those of Tanabe A et al 
[23] and Jugessur A et al [24] conducted on Japanese 
and Norwegian population respectively. The prevalen-
ce of orofacial clefts is more common among Indians 
and oriental populations, where it occurs in 1 every 500 
births or higher [25]. Inspite of this, there has been no 
major study thus far on Indian patients with non-
syndromic CLCP. Our study was, hence, the first report 
on polymorphism in TGF-β3 gene in patients with non-
syndromic cleft lip and palate of Indian origin. This 
study could provide a basis for more elaborate studies 
involving larger number of samples that can explore 
the specific role of TGF-β3gene in more detail in this 
population.  
The general failure to pinpoint the precise molecular 
events that lead to human cleft lip and palate most 
likely stems from our lack of knowledge about the gene 
networks and regulation of gene expression during 
palatal development. While studies such as ours are 
related to individual gene events, they could help by 
contributing to the existing scientific knowledge of 
inter-related gene networks, ultimately leading to a 
better understanding of the pathogenesis of cleft lip and 
palate. In addition to playing an important role in the 
development of palate, TGF-β3 also has some the-
rapeutic possibilities: exogenous TGF3 can correct the 
palatal fusion defect in TGF-β3-null embryos, raising 
the possibility of exogenous supplementation of TGF-
β3 as fetal therapy. Rather than a surgical approach, it 
is known that maternally-administered recombinant 
TGF-β3 can cross the mouse placental barrier. Exo-
genous TGF-β3 is also known to reduce the severity of 
scarring following wound healing in rats [26], raising 
the possibility that some individuals with cleft palate 
caused by genetic abnormalities in the TGF-β3 
pathway might be more prone to excessive scarring 
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following surgical correction, thereby compounding an 
otherwise distressing abnormality. Exogenous 
application of TGF-β3 as an anti-scarring therapy at the 
time of surgical correction of the cleft may also be 
particularly beneficial to such individuals.  
In summary, our study highlights the role for TGF-β3 
in non-syndromic cleft lip and palate patients from the 
Indian sub-continent and points out a potential thera-
peutic intervention to correct the malady. 
Conclusion 
This study indicates that there is strong association 
between the presence of TGF-β3 gene variant with the 
incidence of non syndromic cleft lip and palate and it 
may act as a genetic marker for non syndromic cleft lip 
and palate in this population.  
Studies about such genetic markers of non syndromic 
cleft lip and palate will help us to predict and target at 
the molecular level in treating such problems. A major 
challenge is not only a complete cataloguing of all such 
genes involved in the etiology of non syndromal cleft 
lip palate but identification of their polygenetic nature 
to have a thorough understanding of the craniofacial 
development. The future challenge is to bring this new 
knowledge from the “level of PCR sequencer into the 
clinical realms”. 
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